Genotypes, Phenotypes and Cancer Evolution

Pictured: Professor Nick Turner, Genotypes, Phenotypes and Cancer Evolution Theme Lead
Professor Nick Turner, Genotypes, Phenotypes and Cancer Evolution Theme Lead

Our vision to improve patient outcome through precisely defining when, who and how to treat can only be achieved by innovating in molecular diagnostics and analytic techniques.

This cross-cutting theme will support our research by developing innovative molecular diagnostic techniques, including in blood-based biomarkers and the monitoring of residual disease, to better understand responses to treatment and cancer evolution.

Theme aims

  • To deliver integrated somatic and germline genetic profiling for patients with cancer
  • To integrate liquid biopsies with associated genotyping into routine practice for cancer patients to enhance targeted therapy delivery
  • To focus adjuvant therapy delivery through more exact prognostication of patients with early stage cancer
  • To use the principles of cancer evolution in biomarker development and therapeutic approaches to prevent drug resistance
  • To integrate molecular imaging and radiomics with genotyping and phenotyping

Theme lead

Professor Nicholas Turner (pictured above): Academic Consultant Clinical Oncologist at The Institute of Cancr Research, London, expertise in breast cancer therapeutic biomarker development, including circulating tumour DNA

Blood will tell

Research at The Royal Marsden and the ICR into blood tests known as ‘liquid biopsies’ could represent a major step forward in our ability to detect and monitor breast and other cancers.